Topics

Glioblastoma | Treatment | Immunotherapy | CAR-T-Cells

Home > Publications > Topics > Glioblastoma > Treatment > Immunotherapy > CAR-T-Cells

Bagley SJ, Binder ZA, Lamrani L, Marinari E, Desai AS, Nasrallah MP, Maloney E, Brem S, Lustig RA, Kurtz G, Alonso-Basanta M, Bonté PE, Goudot C, Richer W, Piaggio E, Kothari S, Guyonnet L, Guerin CL, Waterfall JJ, Mohan S, Hwang WT, Tang OY, Logun M, Bhattacharyya M, Markowitz K, Delman D, Marshall A, Wherry EJ, Amigorena S, Beatty GL, Brogdon JL, Hexner E, Migliorini D, Alanio C, O'Rourke DM.
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial.
Nat Cancer. 2024 Jan 12. doi: 10.1038/s43018-023-00709-6. PMID: 38216766. Interventional study˰ ˍ

Zhu N, Chen S, Jin Y, Wang M, Fang L, Xue L, Hua D, Zhang Z, Jia M, Hao M, Zhang C.
Enhancing Glioblastoma Immunotherapy with Integrated Chimeric Antigen Receptor T Cells through the Re-Education of Tumor-Associated Microglia and Macrophages.
ACS Nano. 2024 Apr 16. doi: 10.1021/acsnano.4c00050. PMID: 38626338. Laboratory investigation˰ ˍ

Montoya M, Gallus M, Phyu S, Haegelin J, de Groot J, Okada H.
A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives.
Cells. 2024 Apr 23;13(9):726. doi: 10.3390/cells13090726. PMID: 38727262. Review. ˍ

*Akhavan D, Subham S, Jeppson JD, Aguilar B, Wong RA, Hibbard JC, Hui S, Wong JYC, Forman SJ, Alizadeh D, Brown CE.
Evaluation of the Immunomodulatory Effects of Radiation for Chimeric Antigen Receptor T Cell Therapy in Glioblastoma Multiforme.
Cells. 2024 Jun 21;13(13):1075. doi: 10.3390/cells13131075. PMID: 38994929. Laboratory investigation. ˍ

Agosti E, Garaba A, Antonietti S, Ius T, Fontanella MM, Zeppieri M, Panciani PP.
CAR-T Cells Therapy in Glioblastoma: A Systematic Review on Molecular Targets and Treatment Strategies.
Int J Mol Sci. 2024 Jun 29;25(13):7174. doi: 10.3390/ijms25137174. PMID: 39000281. Review. ˍ

Lu J, Huo W, Ma Y, Wang X, Yu J.
Suppressive immune microenvironment and CART therapy for glioblastoma: Future prospects and challenges.
Cancer Lett. 2024 Aug 12;600:217185. doi: 10.1016/j.canlet.2024.217185. PMID: 39142498. Review. ˍ

Sterner RC, Sterner RM.
EGFRVIII and EGFR targeted chimeric antigen receptor T cell therapy in glioblastoma.
Front Oncol. 2024 Sep 19;14:1434495. doi: 10.3389/fonc.2024.1434495. PMID: 39364321. Review. ˍ

Luo Y, Gadd ME, Qie Y, Otamendi-Lopez A, Sanchez-Garavito JE, Brooks MM, Ulloa Navas MJ, Hundal T, Li S, Jones VK, Lou Y, Patel T, Dronca R, Kharfan-Dabaja MA, Dong H, Quinones-Hinojosa A, Qin H.
Solid cancer-directed CAR T cell therapy that attacks both tumor and immunosuppressive cells via targeting PD-L1.
Mol Ther Oncol. 2024 Oct 5;32(4):200891. doi: 10.1016/j.omton.2024.200891. PMID: 39498357. Laboratory investigation. ˍ

*Sandhanam K, Tamilanban T, Bhattacharjee B, Manasa K.
Exploring miRNA therapies and gut microbiome-enhanced CAR-T cells: advancing frontiers in glioblastoma stem cell targeting.
Naunyn Schmiedebergs Arch Pharmacol. 2024 Oct 9. doi: 10.1007/s00210-024-03479-9. PMID: 39382681. Review˰ ˍ

Sabahi M, Fathi Jouzdani A, Sadeghian Z, Dabbagh Ohadi MA, Sultan H, Salehipour A, Maniakhina L, Rezaei N, Adada B, Mansouri A, Borghei-Razavi H.
CAR-engineered NK cells versus CAR T cells in treatment of glioblastoma; strength and flaws.
J Neurooncol. 2024 Nov 13. doi: 10.1007/s11060-024-04876-z. PMID: 39538038. Review˰ ˍ

Begley SL, O'Rourke DM, Binder ZA.
CAR T Cell Therapy for Glioblastoma: A Review of the First Decade of Clinical Trials.
Mol Ther. 2025 Mar 7:S1525-0016(25)00178-9. doi: 10.1016/j.ymthe.2025.03.004. PMID: 40057825. Review. ˍ

**Gu J, Li J, Xu Y, Zhang G, Xie J, Jia R, Chen W, Lu Z, Chang C, Wen H, Chang LJ, Ma H, Cai Q.
Preliminary exploration of PSMA CAR-T combined with GD2 CAR-T for the treatment of refractory/relapsed gliomas.
J Transl Med. 2025 May 27;23(1):591. doi: 10.1186/s12967-025-06523-1. PMID: 40420236. Interventional study. ˍ

Wang M, Wang Z, Zhang G, Fan J.
Interleukin-enhanced CAR-engineered immune cells in tumor immunotherapy: current insights and future perspectives.
Cytokine. 2025 May 30;192:156973. doi: 10.1016/j.cyto.2025.156973. PMID: 40449036. Review˰ ˍ

Bagley SJ, Desai AS, Fraietta JA, Silverbush D, Chafamo D, Freeburg NF, Gopikrishna GK, Rech AJ, Nabavizadeh A, Bagley LJ, Park J, Jarocha D, Martins R, Sarmiento N, Maloney E, Lledo L, Stein C, Marshall A, Leskowitz RM, Jadlowsky JK, Mackey S, Christensen S, Oner BS, Plesa G, Brennan A, Gonzalez V, Chen F, Barrett D, Colbourn R, Nasrallah MP, Mourelatos Z, Hwang WT, Alanio C, Siegel DL, June CH, Hexner EO, Binder ZA, O'Rourke DM.
Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial.
Nat Med. 2025 Jun 1. doi: 10.1038/s41591-025-03745-0. PMID: 40451950. Interventional study. ˍ

Belokon SV, Kukarskaya VA, Klabukov ID, Shestakova VA, Ivanov SA, Shegay PV, Kaprin AD, Baranovskii DS.
A Critical Review of CAR-T Therapies for Glioblastoma: What's Wrong with the Current Attempts?
Hematol Oncol Stem Cell Ther. 2025 Jun 20. doi: 10.4103/hemoncstem.HEMONCSTEM-D-24-00040. PMID: 40539476. Review. ˍ

*Gatto L, Di Nunno V, Tosoni A, Aprile M, Argento CM, Margotti M, Bartolini S, Franceschi E.
Advances in the Optimization of CAR-T-Cell-Based Therapeutic Approaches to Enhance Antitumor Efficacy in Glioblastoma Treatment.
Oncol Ther. 2025 Jun 21. doi: 10.1007/s40487-025-00355-1. PMID: 40542937. Editorial. ˍ

Chan JTN, Henley-Waters J, Kayhanian S.
Chimeric antigen receptor (CAR)-T-cell therapy for glioblastoma: what can we learn from the early clinical trials? A systematic review.
Neurooncol Adv. 2025 Jun 3;7(1):vdaf115. doi: 10.1093/noajnl/vdaf115. PMID: 40626039. Review. ˍ AI Overview

Hadiloo K, Mostanadi P, Asadzadeh A, Taremi S, Esmaeilzadeh A.
Targeting cancer stem cells with CAR-based immunotherapy: biology, evidence, and future directions.
Cancer Cell Int. 2025 Jul 28;25(1):289. doi: 10.1186/s12935-025-03846-3. PMID: 40722155. Review. ˍ AI Overview

Choi MJ, So EY, Akosman B, Lee YE, Raufi AG, Bertone P, Reginato AM, Chen CC, Lawler SE, Wong ET, Liang OD.
Enabling CAR-T Cell Immunotherapy in Glioblastoma by Modifying Tumor Microenvironment via Oncolytic Adenovirus Encoding Bispecific T Cell Engager.
bioRxiv [Preprint]. 2025 Aug 2:2025.07.30.667708. doi: 10.1101/2025.07.30.667708. PMID: 40766453. Lab investigation. ˍ AI Overview

Barish ME, Aftabizadeh M, Hibbard J, Blanchard MS, Ostberg JR, Wagner JR, Manchanda M, Paul J, Stiller T, Aguilar B, Starr R, Arvanitis L, Ressler JA, Kilpatrick J, Kong Y, Wang D, Forman SJ, D'Apuzzo M, Brown CE, Badie B.
Chlorotoxin-directed CAR T cell therapy for recurrent glioblastoma: Interim clinical experience demonstrating feasibility and safety.
Cell Rep Med. 2025 Aug 15;6(8):102302. doi: 10.1016/j.xcrm.2025.102302. PMID: 40818458. Interventional study. ˍ ClinicalTrrials.gov ID: NCT04214392.

Czyżewski W, Kus-Budzynska K, Sobstyl J, Sojka M, Litak J, Szaliński T, Jeżewski MP, Turek M, Chaurasia B, Mandat T, Torres K, Staśkiewicz G.
CAR-T cell therapy for glioblastoma: advances, challenges, and future directions.
Ann Med Surg (Lond). 2025 Jul 18;87(9):5743-5756. doi: 10.1097/MS9.0000000000003607. PMID: 40901145. Review. ˍ

Li J, Lu L, Duan Y, Huang G, Fang X, Deng Y, Tang F, Jiang F, Dai D.
Global research trends in CAR-T cell therapy for glioblastoma: a bibliometric and visualized analysis.
Discov Oncol. 2025 Sep 29;16(1):1770. doi: 10.1007/s12672-025-03285-6. PMID: 41021151. Bibliometric analysis. ˍ

Walton CM, Bell M, O'Neil R, Sahin O, Choi BD, Fecci PE, Strickland BA.
Chimeric antigen receptor (CAR) T-cell therapy for glioblastoma (GBM): current clinical insights, challenges, and future directions.
J Immunother Cancer. 2025 Oct 31;13(10):e012308. doi: 10.1136/jitc-2025-012308. PMID: 41176315. Review. ˍ

Królikowska A, Tarnowski M.
CAR-T cells immunotherapy in the treatment of glioblastoma.
Cancer Immunol Immunother. 2025 Nov 6;74(12):363. doi: 10.1007/s00262-025-04222-w. PMID: 41196398. Review. ˍ

Parekh D, Patel AH, Khan A, Olojakpoke E, Karpe A, Peelay Z, Patil V.
CAR-T in relapsed refractory high-grade glioma and glioblastoma - who, what, when and how?
Ecancermedicalscience. 2025 Sep 30;19:2001. doi: 10.3332/ecancer.2025.2001. PMID: 41561543. Review. ˍ

Hayat MA, Yu S, Tao G, Ghani MU, Hu J.
Chimeric antigen receptor T cell therapy for glioblastoma: overcoming current barriers and strategies to enhance efficacy for therapeutic implications.
Biochem Pharmacol. 2026 Feb 27;248:117851. doi: 10.1016/j.bcp.2026.117851. PMID: 41765112˰ ˍ